Picton Mahoney Asset Management Grows Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Picton Mahoney Asset Management raised its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 994.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 16,175 shares of the company’s stock after buying an additional 14,697 shares during the period. Picton Mahoney Asset Management’s holdings in RAPT Therapeutics were worth $26,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RAPT. Los Angeles Capital Management LLC raised its stake in RAPT Therapeutics by 138.1% in the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock valued at $405,000 after buying an additional 116,853 shares in the last quarter. Readystate Asset Management LP acquired a new stake in RAPT Therapeutics in the third quarter valued at $36,000. Barclays PLC raised its stake in RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares in the last quarter. JPMorgan Chase & Co. raised its stake in RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after buying an additional 25,130 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after buying an additional 42,636 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Stock Performance

RAPT opened at $1.12 on Tuesday. The business’s 50-day simple moving average is $1.19 and its 200-day simple moving average is $1.50. RAPT Therapeutics, Inc. has a one year low of $0.79 and a one year high of $9.65. The stock has a market capitalization of $39.15 million, a P/E ratio of -0.40 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). On average, equities research analysts forecast that RAPT Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of RAPT Therapeutics in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, RAPT Therapeutics has an average rating of “Hold” and an average price target of $5.29.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.